Patent Number: 7,709,463

Title: Idraparinux (SanOrg34006) for treatment of venous events in patients with deep venous thrombosis

Abstract: The invention relates to a dose of 2.5 mg of the pentasaccharide methyl O-(2,3,4-tri-O-methyl-6-O-sulfo-.alpha.-D-glucopyranosyl)-(1.fwdarw.4)-O-- (2,3-di-O-methyl-.beta.-D-glucopyranosyl uronic acid)-(1.fwdarw.4)-O-(2,3,6-tri-O-sulfo-.alpha.-D-glucopyranosyl)-(1.fwda- rw.4)-O-(2,3-di-O-methyl-.alpha.-L-idopyranosyl uronic acid)-(1.fwdarw.4)-2,3,6-tri-O-sulfo-.alpha.-D-glucopyranoside or a pharmaceutically acceptable salt thereof for use in therapy, in particular for the treatment of venous thromboembolic events in patients with deep venous thrombosis.

Inventors: Van Amsterdam; Ronald Gijsbertus Maria (Oss, NL)

Assignee: Sanofi-Aventis

International Classification: A61K 31/715 (20060101); A61K 31/70 (20060101); A61K 31/7028 (20060101); A61K 31/737 (20060101)

Expiration Date: 5/04/12018